The Center for Reproductive Health Sciences is thrilled to announce that research from the lab of Dineo Khabele, MD, was recently published in BMC Cancer. The research article is titled “The Tie2 antagonist rebastinib reduces ovarian cancer growth in a syngeneic murine model” and was authored by Gupta et al.
The researchers of this study concluded that “Rebastinib plus chemotherapy extends survival in a syngeneic murine model of ovarian cancer. Rebastinib alters proportions of immune cell subsets, increases cytotoxic T cells in ascites, and alters gene expression in tumor cells and macrophages.”